INT-747

DRUG2 trials

Sponsors

Intercept Pharmaceuticals

Conditions

Diabetes Mellitus, Type IIFatty LiverLiver Cirrhosis, Biliary

Phase 2

Study of INT-747 in Patients With Diabetes and Presumed NAFLD

CompletedNCT00501592

Intercept PharmaceuticalsDiabetes Mellitus, Type II, Fatty Liver

Start: 2007-07-31End: 2009-04-30Updated: 2012-04-20

Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)

TerminatedNCT00550862

Intercept PharmaceuticalsLiver Cirrhosis, Biliary

Start: 2007-10-31End: 2010-12-31Updated: 2024-02-06

Related Papers

Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.

2014-12-11419 citations

Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.

2013-05-30708 citations